This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license. This work is licensed under a Creative Commons Attribution 4.0 International ...

In preliminary results from the phase II iMMagine-1 trial released today, the BCMA-directed chimeric antigen receptor (CAR) T-cell therapy anitocabtagene autoleucel (anito-cel) did not elicit any ...

1Louis V. Gerstner Jr. Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, New York.

Mol Cancer Ther (2024) 23 (11): 1515.

Under its 2025 Physician Fee Schedule (PFS), the Centers for Medicare & Medicaid Services (CMS) announced that physicians will be paid, on average, nearly 3% less next year compared with 2024 ...

Cancer Immunology Research publishes outstanding original articles reporting major advances in cancer immunology that span the discipline from basic investigations in host-tumor interactions to ...

1Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan. 2Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan.

“We look forward to achieving our goal of being a catalyst for the next big discovery.” ...

1The Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. Search for other works by this author on: 1The Lineberger Comprehensive Cancer ...

The Blood Cancer Discovery Award for Outstanding Journal Article is awarded to the corresponding author of a peer-reviewed, original Research Article or Brief published within the previous two years ...

First Disclosures in Molecular Cancer Therapeutics present drugs for the first time in published literature, accompanied by pertinent translational investigations. Submissions are assessed based on ...